Core Insights - Financial giants are showing a bearish sentiment towards Johnson & Johnson, with 75% of traders indicating bearish tendencies and only 16% being bullish [1] - The analysis of options trading reveals a significant focus on a price range between $150.0 and $230.0 over the past three months [2] - Recent options activity indicates a notable bearish sentiment, with large trades in both calls and puts [7] Options Activity - The volume and open interest trends for Johnson & Johnson's options suggest a high level of liquidity and interest, particularly within the identified price range [3] - A detailed overview of the largest options trades shows that bearish sentiment is prevalent, with significant put and call volumes observed [7] Company Overview - Johnson & Johnson is recognized as the world's largest and most diverse healthcare firm, focusing on innovative medicine and medtech after divesting its consumer business [8] - The company generates over half of its total revenue from the United States, with its drug division concentrating on immunology, oncology, and neurology [8] Analyst Insights - Market analysts have set a consensus target price of $197.0 for Johnson & Johnson, reflecting cautious optimism amid the current bearish options activity [9][10] - The stock price is currently at $206.0, showing a slight increase of 0.28%, with upcoming earnings expected in 49 days [12]

Core Viewpoint - Investors are showing a bullish sentiment towards Johnson & Johnson (NYSE: JNJ), indicated by significant options trading activity, suggesting that large investors may anticipate upcoming developments [1][2]. Options Trading Activity - A total of 38 uncommon options trades for Johnson & Johnson were identified, with 26 calls amounting to $2,847,461 and 12 puts totaling $701,701, reflecting a mixed sentiment among traders [2][3]. - The overall sentiment from big-money traders is approximately 50% bullish and 36% bearish, indicating a notable interest in the stock [3]. Price Targets - The targeted price range for Johnson & Johnson's stock over the last three months has been identified between $145.0 and $255.0, based on the volume and open interest of options contracts [4]. Volume and Open Interest - The analysis of volume and open interest provides insights into the liquidity and investor interest in Johnson & Johnson's options, particularly within the strike price range of $145.0 to $255.0 over the past 30 days [5]. Current Market Status - Johnson & Johnson is recognized as the world's largest and most diverse healthcare firm, focusing on innovative medicine and medtech after divesting its consumer business, Kenvue, in 2023 [10]. - The company’s drug division is concentrating on three main therapeutic areas: immunology, oncology, and neurology, with over half of its total revenue generated in the United States [10]. Analyst Ratings - Recent professional analyst ratings indicate an average price target of $190.0 for Johnson & Johnson, with one analyst revising their rating downward to Hold [11][12]. Trading Metrics - The current trading volume for Johnson & Johnson stands at 7,976,739, with the stock price at $202.11, reflecting a 1.06% increase [14].

Core Insights - Financial giants are showing a bullish sentiment towards Johnson & Johnson, with 58% of traders being bullish and only 23% bearish, indicating strong market interest [1] - The projected price targets for Johnson & Johnson range from $145.0 to $190.0, suggesting significant upside potential based on recent trading activity [2] - Analysts have set a consensus target price of $203.0, with one analyst from JP Morgan maintaining a Neutral rating and another from Guggenheim upgrading to Buy with a target of $206 [11][12] Options Activity - A total of 17 unusual trades were identified, with 14 calls valued at $935,177 and 3 puts valued at $283,763, reflecting a preference for bullish positions [1] - The volume and open interest data for options indicate heightened liquidity and interest in the $145.0 to $190.0 strike price range over the past 30 days [3][4] - Noteworthy options activity includes various trades with significant total trade prices, such as a bullish call trade with a total price of $185.4K at a strike price of $180.00 [8] Company Overview - Johnson & Johnson is the largest and most diverse healthcare firm globally, focusing on innovative medicine and medtech after divesting its consumer business in 2023 [9] - The drug division is concentrating on three main therapeutic areas: immunology, oncology, and neurology, with over half of its revenue generated in the United States [9] - Current trading volume for Johnson & Johnson is 4,449,853, with the stock price at $177.32, reflecting a slight increase of 0.36% [14]

Let's get a Wednesday edition of Kramer's Mad Dash. The best non-bank is J&J. I mean, this J&J quarter, it may set, you know, they're not talking that much about tariffs.Uh, that is going to happen. They're probably a later thing. But I was stunned.The oncology sales are incredible, up 24%. They have new bladder cancer. Uh, I nothing's a cure, but great maintenance that I think uh medtech finally came back.It was really sensational. Uh, a lot of people were thinking that medtech was weaker. uh neuroscience ...